Velo3D: The Margin Story Is Real, But So Is The Dilution Axe Hanging Over It

# Velo3D: The Margin Story Is Real, But So Is The Dilution Axe Hanging Over It

There is a version of Velo3D's story that will get you excited, and there is a version of the story that will get you liquidated. Right now the stock is sitting around $11.20, down hard off its mid-August levels near $15.38, and it's easy to read that decline as the bears winning. But the bears are arguing about the past. The bulls are arguing about the fourth quarter, and that's where the whole thing gets decided.

Let's start with why anyone would bother with a metal 3D printing company that still bleeds cash.

Velo3D's Q2 2026 report, handed down August 11, was the inflection everyone has been circling. Revenue came in at roughly $20.7M, up 52.3% year over year and well clear of estimates near $13–14M. More importantly, gross margin flipped to positive 21.5%, versus negative 11.7% a year earlier. Management raised full-year revenue guidance to $65M–$75M from $60M–$70M, and pointed to gross margins above 30% in the second half plus positive EBITDA in H2. Backlog doubled to $31M. Cash sat at $91.1M.

That is a company that looks like it might actually become a company. The Livermore "Forge 1" facility, which opened July 21 and reportedly triples manufacturing capacity, is the linchpin. Management expects it to start producing revenue-generating parts in Q4. If it does, the whole margin thesis compounds. If it doesn't, you're buying a story.

Now the part the bulls quietly skip over.

Q2 also posted a $11.5M GAAP net loss and negative $8.1M adjusted EBITDA. Non-GAAP EPS of negative $0.30 missed consensus. And here is the ugly, unglamorous detail that tends to decide small-cap fates: 1H 2026 operating cash burn was about $39.5M. The company is funding its expansion by tapping equity markets, backed by a $100M ATM facility and a $97.3M shelf registration set up this year. Dilution isn't a risk here. Dilution is the business model.

Then there's the inventory. Roughly $24.1M in reserves against $27.6M in net inventory—an 87% reserve-to-inventory ratio. That's a company flagging that a big chunk of what it's building may not sell at full value. Add un-remediated material weaknesses in IT, inventory, and accounting, a going-concern note, and customer concentration where the top three names were 34% of first-half revenue, and you've got a balance sheet that institutional money tends to eyeball skeptically. That's why institutional ownership is thin—about 14 hedge funds in Q2—while short interest sits at a punishing ~30.4% of the float.

And the governance questions aren't cosmetic. Morpheus Research, running an activist-style critique, flags Velo trading at a large price-to-sales premium to peers, notes CEO Arun Jeldi pledged nearly 25% of his stake for a margin loan, and questions the durability of the reported revenue growth and the SpaceX ties. Jim Cramer publicly told viewers to cap any position at "a quarter position" on the strength of inconsistent revenue growth.

So where do I actually stand?

I think the operational turn is real, and I think the market is pricing it as if it isn't. A company going from negative gross margins to 21.5% while tripping its way toward 30% with a doubling backlog is not a fraud. The RPS revenue mix expansion toward 25–30% of sales would also give this a spine of revenue predictability it's never had. If Q4 confirms Livermore is shipping, this stock has a lot of room to re-rate against that ~$22–23 consensus target from a group that's unanimously "Strong Buy"—though keep in mind that's a sample of roughly four analysts, which is closer to a rumor than a valuation anchor.

But I'm not buying the momentum on faith. The cash burn is the leash. At $39.5M in first-half burn against $91.1M in cash, the ATM and shelf aren't a contingency plan—they're the primary plan. And with short interest near a third of the float, any miss on the Livermore timeline won't just hurt the stock; it'll get shorted to death and then squeeze on its own gravity. Beta near 2.6 means you're already leveraged into this without asking.

Here's my read: Velo3D is a Q4 bet dressed up as a momentum trade. The margin inflection is genuine, the backlog is growing, and the SpaceX/Raptor 4 qualification gives it a customer base that matters. But you're paying for it with future shares, living through a material-weakness audit cycle, and leaning on a single facility to prove the thesis in a single quarter.

Own it like someone who knows the dilution axe is real and the catalyst is exactly one month away on November 9. Size it like Cramer was right—quarter position, not conviction. Watch Livermore's Q4 output like a hawk, not the analyst notes. And when that report prints, don't fall in love with the direction of the margin line. Fall in love with whether they actually shipped parts. Everything else is noise.